Bloomage BioTechnology (688363.SS) Earnings Analysis
Bloomage BioTechnology (688363.SS) next reports earnings on 2026-08-28, consensus EPS 0.2415 CNY. Last quarter (2026-04-30) it missed with EPS 0.13 CNY vs 0.2705 CNY est (-51.9%). It has beaten estimates in 1/5 recent quarters (20%). Trailing P/E 71.08.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does 688363.SS next report earnings?
| Next earnings date | 2026-08-28 |
|---|---|
| Consensus EPS estimate | 0.2415 CNY |
| Revenue estimate | 1.02B |
688363.SS earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-04-30 | 0.13 CNY | 0.2705 CNY | -51.9% | Miss |
| 2026-02-28 | 0.08133 CNY | 0.2286 CNY | -64.4% | Miss |
| 2025-04-25 | 0.21 CNY | 0.63 CNY | -66.7% | Miss |
| 2025-02-27 | -0.41 CNY | 0.28 CNY | -246.4% | Miss |
| 2024-08-23 | 0.7 CNY | 0.64 CNY | +9.4% | Beat |
Beat rate: 1/5 (20%) over reported quarters with consensus data.
688363.SS valuation and analyst view
| Trailing P/E | 71.08 |
|---|---|
| Trailing EPS | 0.55177 CNY |
| Price / book | 2.48 |
| Dividend yield | 0.50% |
| Market cap | 7.54B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is Bloomage BioTechnology (688363.SS)'s next earnings date?
Bloomage BioTechnology is next scheduled to report on 2026-08-28, with a consensus EPS estimate of 0.2415 CNY and revenue estimate of 1.02B.
Did 688363.SS beat earnings last quarter?
In its 2026-04-30 report, 688363.SS posted EPS of 0.13 CNY versus a 0.2705 CNY estimate — a miss of 51.9%.
What is 688363.SS's earnings track record?
Over the last 5 reported quarters with consensus data, 688363.SS beat estimates 1 times (20%).
What is 688363.SS's current P/E ratio and EPS?
688363.SS trades at a trailing P/E of 71.08 on trailing EPS of 0.551773772929921 CNY.
What do analysts rate 688363.SS?
688363.SS has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.